Author

Jonathan R. Brody

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B122: The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design

Recent data published from the RASolute 302 trial (NCT06625320), showing that RAS inhibition nearly doubles median survival to 13.2 months compared to 6.7 months with standard-of-care chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC), received an ovation when presented at the 2026 ASCO Oncology m...

Jonathan R. Brody · Cancer Research · 0 citations

Sep 2026

The post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma.

Overall, it is found that the post-transcriptional regulator HuR facilitates immune evasion in PDAC by constraining T-cell function, identifying HuR blockade as a promising therapeutic strategy in combination with immunotherapies.

Yi-Fei Guo, Jennifer M. Finan, Alexandra Q. Bartlett et al. · Cancer immunology research · 0 citations